AI Article Synopsis
Article Abstract
Despite some major progress made in developing tuberculosis (TB) vaccine strategies, with a dozen novel vaccines currently in the clinical pipeline, the world is still missing an effective TB vaccine. This questions whether any major breakthroughs can be achieved without making a drastic departure from the current strategy, which creates a state of 'near-natural immunity', imitating the natural immunity developed after Mycobacterium tuberculosis (Mtb) infection. Here, we argue instead that mounting evidence suggests an effective strategy ought to induce a state of all-around 'un-natural' immunity comprising trained innate immunity (TII), tissue-resident memory T cells (T), and anti-Mtb surface antibodies in the lung. Thus, here we summarize the latest information, thinking, and development in the field of TB and vaccines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.it.2018.01.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of an effective tuberculosis (TB) vaccine has been challenged by incomplete understanding of specific factors that provide protection against (Mtb) and the lack of a known correlate of protection (CoP). Using a combination of samples from a vaccine showing efficacy (DarDar [ NCT00052195 ]) and Bacille Calmette-Guerin (BCG)- immunized humans and nonhuman primates (NHP), we identify a humoral CoP that translates across species and vaccine regimens. Antibodies specific to the DarDar vaccine strain ( ) sonicate (MOS) correlate with protection from the efficacy endpoint of definite TB.
View Article and Find Full Text PDFComplications of the Bacillus Calmette-Guerin vaccine as an early warning sign of inborn errors of immunity: a report of 197 patients.
Front Immunol
December 2024
Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: According to the WHO's recommendation for developing countries, Bacillus Calmette-Guerin (BCG) vaccination has been implemented in some countries as part of national vaccination programs at birth. Although it is generally considered safe, some complications may occur; including BCGitis (local) or BCGosis (systemic), ranging from mild like local abscesses to fatal impediments like osteomyelitis and disseminated BCG infection. This study aimed to determine the spectrum of inborn errors of immunity (IEI) in BCG-vaccinated neonates experiencing local or systemic complications.
View Article and Find Full Text PDFIntradermal Versus Subcutaneous Immunization: Effects of Administration Route using a Lipid-PLGA Hybrid Nanoparticle Tuberculosis Vaccine.
Eur J Pharm Sci
December 2024
Department of Infectious Diseases, LUCID, Leiden University Medical Center (LUMC), The Netherlands.
Tuberculosis (TB) remains a significant global health challenge, latently affecting around a quarter of the global population. The sole licensed TB vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), shows variable efficacy, particularly among adolescents and adults, underscoring the pressing need for more effective vaccination strategies. The administration route is crucial for vaccine efficacy, and administration via the skin, being rich in immune cells, may offer advantages over conventional subcutaneous routes, which lack direct access to abundant antigen-presenting cells.
View Article and Find Full Text PDFEffectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.
Lancet Microbe
December 2024
Amsterdam University Medical Centres, Amsterdam, Netherlands; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
Background: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development. We aimed to assess whether the effectiveness of the Bacillus Calmette-Guérin (BCG) vaccine for prevention of Mycobacterium tuberculosis infection was consistent with that for prevention of tuberculosis disease.
View Article and Find Full Text PDFHealth inequalities in respiratory tract infections - beyond COVID-19.
Curr Opin Infect Dis
December 2024
Division of Medical Sciences, Northern Ontario School of Medicine University, Thunder Bay, Ontario, Canada.
Purpose Of Review: To discuss recent findings on the global burden of respiratory tract infections in underprivileged populations, highlighting the critical role of socioeconomic factors in the incidence and severity of these diseases, with a particular focus on health disparities affecting Indigenous communities.
Recent Findings: Pulmonary tuberculosis and lower respiratory tract infections, particularly those caused by Streptococcus pneumoniae and respiratory syncytial virus (RSV), continue to disproportionally impact populations in low-income countries and Indigenous communities worldwide. Indigenous children <5 years old bear the highest global burden of RSV infection, reflecting persistent social inequalities between Indigenous and non-Indigenous populations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!